TY - JOUR
T1 - Sintered dicalcium pyrophosphate decreases bone turnover rate in osteoporotic rat
T2 - A study on serum biochemical bone turnover markers
AU - Yang, Kai Chiang
AU - Yen, Ko Chung
AU - Huang, Jian Yuan
AU - Wu, Chang Chin
AU - Lin, Feng Huei
PY - 2011
Y1 - 2011
N2 - Sintered dicalcium pyrophosphate (SDCP) is a synthetic pyrophosphate analog that could be utilized in the treatment for osteoporosis. In this study, an ovariectomized (OVX) Wistar rat model is applied to evaluate the effects of SDCP on biochemical bone turnover markers relative to its effects on bone mass. OVX rats were treated with SDCP in the dose of 0.75 mg/kg daily for continued 13weeks. Rats were sacrificed after predetermined periods; serum levels of bone turnover markers were evaluated. Parallel histological evaluation and bone ashes of the long bones of four limbs were performed. Results showed that the serum level of bone resorption marker (type I collagen fragments) for rats treated with SDCP decreased, and the levels of bone formation markers (alkaline phosphatase [ALP], osteocalcin and osteopontin) also decreased significantly.These findings reveal the bone turnover rate decreased. Histological examinations of distal femoral metaphysis revealed the OVX rats ingested with SDCP restored the architectures of trabecular bone and decreased the porosity. This finding was consistent with the increase in serum tartrate-resistant acid phosphatase 5b level, an indicator that represents the number of osteoclast, which indicates an increase of bony tissues. The analyses of limbs bone ashes showed a significant increase in bone mineral contents. This study indicates that the SDCP inhibits the bone resorption rate to restore the bone mass in the OVX rats that could be applied in clinic in the future. Crown
AB - Sintered dicalcium pyrophosphate (SDCP) is a synthetic pyrophosphate analog that could be utilized in the treatment for osteoporosis. In this study, an ovariectomized (OVX) Wistar rat model is applied to evaluate the effects of SDCP on biochemical bone turnover markers relative to its effects on bone mass. OVX rats were treated with SDCP in the dose of 0.75 mg/kg daily for continued 13weeks. Rats were sacrificed after predetermined periods; serum levels of bone turnover markers were evaluated. Parallel histological evaluation and bone ashes of the long bones of four limbs were performed. Results showed that the serum level of bone resorption marker (type I collagen fragments) for rats treated with SDCP decreased, and the levels of bone formation markers (alkaline phosphatase [ALP], osteocalcin and osteopontin) also decreased significantly.These findings reveal the bone turnover rate decreased. Histological examinations of distal femoral metaphysis revealed the OVX rats ingested with SDCP restored the architectures of trabecular bone and decreased the porosity. This finding was consistent with the increase in serum tartrate-resistant acid phosphatase 5b level, an indicator that represents the number of osteoclast, which indicates an increase of bony tissues. The analyses of limbs bone ashes showed a significant increase in bone mineral contents. This study indicates that the SDCP inhibits the bone resorption rate to restore the bone mass in the OVX rats that could be applied in clinic in the future. Crown
KW - Bisphosphonates
KW - Bone turnover markers
KW - Osteoporosis
KW - Pyrophosphate analog
KW - Sintered dicalcium pyrophosphate
UR - http://www.scopus.com/inward/record.url?scp=79960459635&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79960459635&partnerID=8YFLogxK
U2 - 10.1016/j.biomag.2010.10.004
DO - 10.1016/j.biomag.2010.10.004
M3 - Review article
AN - SCOPUS:79960459635
SN - 2210-5220
VL - 1
SP - 46
EP - 51
JO - Biomedicine and Aging Pathology
JF - Biomedicine and Aging Pathology
IS - 1
ER -